Back to results
US 10,894,950 B2Granted
TAL-Tet1 fusion proteins and methods of use thereof
AssigneeThe General Hospital Corporation
InventorsJ. Keith Joung, Morgan Maeder, James Angstman
Life of this patent
Estimating the term…
Abstract
Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array or zinc finger, and a catalytic domain comprising a sequence that catalyzes hydroxylation of methylated cytosines in DNA, and methods of use thereof.
Claims14
A nucleic acid encoding a fusion protein comprising
- an engineered transcription activator-like (TAL) effector repeat array or a zinc finger protein DNA-binding domain that is capable of specifically binding to a DNA sequence that is within 250 bp of a CpG diresidue in a mammalian cell, fused to
- a catalytic domain comprising a catalytic domain of Tet1 comprising amino acids 1580-2052 of SEQ ID NO:
- 2, and excluding amino acids 584-624 of SEQ ID NO:2, that is capable of catalyzing hydroxylation of methylated cytosines in DNA.
A method of reducing methylation of a CpG diresidue in a mammalian cell, the method comprising contacting the cell with a nucleic acid encoding a fusion protein comprising
- an engineered transcription activator-like (TAL) effector repeat array or a zinc finger protein DNA-binding domain that is capable of specifically binding to a DNA sequence that is within 250 bp of a CpG diresidue in a mammalian cell, fused to
- a catalytic domain comprising a catalytic domain of Tet1 comprising amino acids 1580-2052 of SEQ ID NO:
- 2, and excluding amino acids 584-624 of SEQ ID NO:2, that is capable of catalyzing hydroxylation of methylated cytosines in DNA, and wherein the fusion protein reduces methylation of the CpG diresidue.
Dependencies are inferred from the claim text.